CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study

CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S

Harold Glucksberg, Rainer Storb, A Fefer et al. · Transplantation · 1974 · 3.7K citations

Medicine, Hematology, Immunology +14

Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia

Rainer Storb, H. Joachim Deeg, John Whitehead et al. · New England Journal of Medicine · 1986 · 1.5K citations

Medicine, Hematology, Immunology +14

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations

Medicine, Medicinal Chemistry, Pharmacology +17

Active participation of CCR5+CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease

Masako Murai, Hiroyuki Yoneyama, Akihisa Harada et al. · Journal of Clinical Investigation · 1999 · 304 citations · Full text

Life Sciences, Immunology, Pathology +17

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser et al. · The Lancet Haematology · 2019 · 281 citations

Medicine, Immunology, Pharmacotherapy +16